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Multiple endocrine neoplasia type 1 (MEN1) 
is an inherited endocrine tumor syndrome, 
predominantly characterized by tumors of the 
parathyroid glands, gastroenteropancreatic 
tumors, pituitary adenomas, adrenal adenomas 
and neuroendocrine tumors (NETs) of the thy-
mus, lungs and/or stomach. MEN1 is caused 
by germline mutations of the MEN1 tumor 
 suppressor gene.
A clinical and practical definition of a patient 
with MEN1 is a case with at least two out of 
the three main MEN1-related endocrine tumors 
(parathyroid hyperplasia/adenomas, entero-
pancreatic endocrine tumors and pituitary 
tumors). Currently, genetic predisposition to 
MEN1 may be established by demonstrating a 
germline mutation in the MEN1 gene.
Thanks to the collaboration of the MEN1 
families involved, positional cloning allowed 
mapping of the gene to a specific chromosomal 
region by linkage analysis. Eventually, the correct 
gene among all possible candidate genes within 
that particular region was identified.
After the gene was identified, a study of 
its physiological function was performed. In 
numerous tissues, the MEN1 gene is expressed; 
however, an intact function is only needed in a 
restricted number of organs in order to suppress 
cell division. It appeared that the gene product 
called menin has a dual function in modifica-
tion of histone proteins and regulation of DNA 
transcription, according to a  coactivator and/or 
corepressor function [1,2].
In MEN1, most of the mutations are clearly 
inactivating, in accordance with the notion that 
the MEN1 gene is a tumor suppressor gene. 
A clear correlation between genetic events and 
the variable clinical expression of MEN1 has 
not yet been established [3,4]. Apparently, there 
are no mutational hotspots in the MEN1 gene. 
However, it appears that in the MEN1 syndrome, 
clinical expression differs between families. This 
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Due to the variable expression of multiple endocrine neoplasia type 1 (MEN1), it is difficult 
to predict the course of the disease. However, knowledge about the normal function of the 
MEN1 gene product, together with the effects of cellular derangement by subsequent genetic 
events, has increased considerably. At first, the possible existence of a genotype–phenotype 
correlation is discussed. Thus, mild- and late-onset phenotypes may be distinguished from 
more malignant phenotypes depending on the character of the primary MEN1 disease 
gene mutation. Subsequently, tumor-promoting factors such as gender, additional 
genetic mutations and ecogenetic factors may contribute to the course of the disease. 
New developments in management are based on the knowledge and experience of the 
multidisciplinary teams involved. Finally, the metabolic effects of MEN1 mutations in aged 
patients are discussed. Early identification of predisposition to the disease, together with 
knowledge about the natural history of specific mutations, risks of additional mutations and 
periodic clinical monitoring, allow early treatment and may improve life expectancy and quality 
of life.
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may be the result of the specific MEN1 gene mutation in a family 
(genotype–phenotype correlation). Moreover, among individual 
members within the same family, clinical expression can also vary, 
possibly due to additional genetic or epigenetic factors. 
As a rule, the development of a tumor depends on a series of 
genetic events, in other words, multistep tumorigenesis. Thus, 
additional cosegregating modifying factors such as germline 
gene mutations in other genes are likely to play a role in the 
interfamilial variability of MEN1. Further understanding of 
the genetic aspects of MEN1 and the pathogenesis of MEN1-
related tumors could enable more tailored clinical screening and 
 treatment strategies.
In this review, recent reports on aberrant clinical expression 
of MEN1 have been discussed, which may allow a glimpse into 
the pathogenesis of this intriguing disorder. In addition, new 
developments in clinical management are summarized. Finally, 
the consequences for future care are considered.
Function of the intact MEN1 gene product
The intact MEN1 gene (wild-type) product, menin, functions as 
an adaptor protein that is involved in interactions with multiple 
protein partners (Figure 1).
As a transcriptional coregulator, menin may function as a 
 coactivator or corepressor by recruiting histone-modifying 
enzymatic activity [1]. As a coactivator, menin is involved in the 
 regulation of histone methylation, by recruiting the mixed-lineage 
leukemia (MLL) proteins MLL1 and MLL2. In this way, menin can 
bind to nuclear receptors and activate nuclear receptor- mediated 
gene transcription. By tethering histone deacetylase activity to 
genes, menin can serve as a repressor of transcription.
As menin shows no clear homology to other known proteins, 
structural information on menin is critical for  understanding its 
role as a tumor suppressor protein and as a cofactor of MLL fusion 
proteins. Knowledge about the 3D structure may elucidate the 




























































The menin pocket domain
has a dual function:
Stimulation of trimethylation
Inhibition of JunD-activated 
transcription
Interaction with pocket 
domain not proven yet
Figure 1. The normal function of menin. The normal function of menin is preservation of differentiation of the cell by modification of 
histone proteins and transcription of genes responsible for inhibition of cell division. Green arrows indicate stimulation of apoptosis, cell 
differentiation, DNA repair and endocrine metabolic functions, and inhibition of cell division is indicated in pink. In multiple endocrine 
neoplasia type 1 tumors, inactivating mutations in the MEN1 gene result in alterations of histone protein modifications: both 
deacetylation (left) and trimethylation (right) are repressed. Consequently, the normal function of menin acting as corepressor and 
coactivator of gene transcription is disabled.  
AKT: Serine/threonine protein kinase (also known as PKB); ASK: Activator of S-phase kinase; E2: Estradiol; ER: Estrogen receptor; 
FANCD: Fanconi anemia group D2 protein; GSK3: Glycogen synthase kinase; hAsh2: Human absent, small or homeotic discs;  
HDAC: Histone deacetylase; VDR: Vitamin D receptor.
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Recently, the crystal structure of menin in Nematostella vect-
ensis was reported [5]. It appears that the consensus interaction 
motif LXXLL of menin is well conserved and is located in an 
α-helix. 
Huang et al. determined the crystal structure of human menin 
in its free form and presented complexes with MLL1 or JunD 
peptides. They showed that the same pocket domain in menin 
binds both MLL and JunD but has opposite effects on transcrip-
tion. So, as expected, in the interaction with MLL and JunD the 
menin molecule appears to have a dual function instead of acting 
as a bridging factor [6]. On the other hand, the structural basis for 
the molecular control mechanism of cofactor binding to homo- 
and heterodimer nuclear receptors was recently published [7]. In 
general, modeling gene mutations into this structure will be helpful 
in determining the effects on protein function. 
Menin is active in many functions, both in early development, 
as well as in repression of cell proliferation. MEN1-null mutant 
mice have indicated that menin is essential for viability [8]. Menin 
is involved in pancreatic islet cell development and function. Later 
on, it is active in many cellular processes, including gene tran-
scription regulation, DNA replication, DNA repair and signal 
transduction.
Menin target genes that are important for development and pro-
liferation include homeobox domain (HOX ) genes, the CDKN2C 
and CDKN1B cyclin-dependent kinase-inhibiting genes, the 
human telomerase (hTERT ) gene and nuclear receptor target genes 
[1,9–11]. The MEN1-related genes MLL, p18 and p27 are predomi-
nantly expressed in endocrine organs like pituitary and pancreatic 
islets [12].
Loss of menin function & tumor growth
Homeobox genes are potential targets for menin during embryonic 
development. Disruption of the MEN1 gene in mice results in 
defects in development of multiple organs, including pancreatic 
islets. Homozygous disruption of the MEN1 gene causes embry-
onic lethality [8]. A MEN1 gene mutation may be completely 
detrimental to the gene’s function. It may also result in a protein 
product with some residual function. An aberrant menin protein 
may be impaired in its function by several mechanisms, as menin 
can interact with many different proteins. Possibly, germline muta-
tions in the MEN1 gene selectively affect the binding of menin to 
its partners, leading to distinct phenotypes.
The type of missense mutation (e.g., replacement of argi-
nine with glycine) may have a differential effect on the func-
tion of menin [13]: in-frame or missense mutations differ from 
frameshift/nonsense mutations [14]. Missense and in-frame muta-
tions may affect the interactions of a menin domain with trans-
cription factors such as JunD, Smad3 and NF-κB and nuclear 
receptors [1], or impair sensitization to apoptosis from caspase-3, 
p53 or p21 [15]. A MEN1 gene missense mutation may result in 
protein instability and enhanced and early proteolytic degradation 
via the ubiquitin–proteasome pathway [16–18].
It was generally assumed that, in contrast to MEN2, in MEN1 
there is no clear genotype–phenotype correlation [3,4]. However, 
several reports challenge this assumption [19].
Familial aberrant expression
Mild- versus late-onset phenotypes
To date, several disease-related MEN1 gene intron mutations 
have been reported [3]. These intron mutations may affect mRNA 
splicing and cause mild phenotypes, with late and relatively low 
penetrance of the disease [20]. However, clinical expression at a 
young age may occur. This may be explained by interpatient 
 variations in gene transcription and translation of the MEN1  
gene [21].
MEN1 Burin
Four large kindreds from the Burin peninsula/Fortune Bay 
area of Newfoundland were investigated [22–24]. They showed 
prominent features of prolactinomas, in addition to carcinoids 
and parathyroid tumors. A nonsense mutation in the MEN1 gene 
has been found to be responsible for the disease in the affected 
members in all four of the MEN1 Burin families. This suggests 
that either a common ancestral mutation in the MEN1 Burin gene 
or a modifying gene on 11q13 is responsible for this prolactinoma 
variant of MEN1 [21]. It would appear that they do not represent 
an early stage of MEN1.
Familial isolated hyperparathyroidism
Familial isolated primary hyperparathyroidism (pHPT) is an 
autosomal dominant disorder that can represent an early stage 
of either MEN1 caused by an allelic variant of the MEN1 
gene, or of hyperparathyroidism (HPT)-jaw tumor syndrome. 
Alternatively, the condition can be caused by an allelic variant of 
the HRPT2 (hyperparathyroidism 2) gene, or caused by another 
mutant locus. Interestingly, the major proportion of MEN1 
gene germline mutations that have been found in familial iso-
lated pHPT are seemingly mild missense mutations or in-frame 
deletions [25]. 
Useful information about the stability of specific menin 
mutants was obtained by investigation of proteasomal degrada-
tion. It appeared that certain protein mutants caused by missense 
and in-frame mutations are fairly stable and retain intrinsic bio-
logical activity. They may be  associated with incomplete clinical 
 phenotypes [18].
More malignant phenotypes: predominant mutations in MEN1 
pancreatic NETs
Schaaf performed mutation analysis of the MEN1 gene in 
tumors from 306 patients with MEN1, and found that patients 
with gastroenteropancreatic tumors more often had truncat-
ing mutations, very likely leading to completely inactivated 
menin [26].
Two recent case reports showed families with a high pen-
etrance of malignant NETs of the pancreas [27,28]. Both these 
families carried germline mutations that completely abolish 
menin function.
Functional analysis of the mutant protein revealed severely 
reduced protein stability [16], reduced binding to JunD [21], 
reduced binding to the estrogen receptor-α [29] and loss of histone 
methylation recruiting capacity. Thus, functional analysis of this 
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potentially mild missense MEN1 gene mutation shows that the 
protein product is in fact completely inactivated.
Tumor-promoting factors
Effect of gender
The prevalence and probability of pancreatic tumors among 
patients with MEN1 were higher in males than in females. This 
difference was due to the differential occurrence of gastrinomas 
[30]. The prevalence and probability of developing pituitary adeno-
mas were significantly greater in females. Thymic tumors are 
found nearly exclusively in males with MEN1 [30]. However, a 
different distribution was found in Japan [31].
The difference in clinical expression between the genders may 
be explained by difference in transcription regulation of estrogen 
and androgen receptors. Menin can act as a coactivator of nuclear 
hormone receptors, including estrogen and possibly androgen 
receptors. A defect in the MEN1 gene together with gender- 
specific differences in concentrations of the hormones involved 
and tissue-specific distribution of their receptors may contribute 
to the observed gender-specific differences in the prevalence of 
 prolactinoma and gastrinoma.
Additional genetic effects
Loss of heterozygosity: the AIP gene
In agreement with the tumor suppressor function of the menin 
protein, MEN1-associated tumors reveal loss of the nonmutated 
(wild-type) allele of the MEN1 gene. This second genetic defect 
is not present in the germline but is a somatic mutation, and often 
involves the deletion of multiple genes in the same chromosomal 
region (loss of heterozygosity).
The chromosomal locus containing the gene encoding the aryl 
hydrocarbon receptor-interacting protein (AIP) is in the same 
region on 11q13 that also contains the MEN1 gene. Recently, 
it has been demonstrated that inactivating mutations in this AIP 
gene are associated with predisposition to pituitary adenoma 
[32], indicating that AIP can also act as a tumor suppressor [33,34]. 
The tumor suppressor genes AIP and MEN1 are located 3 Mb 
apart.
Concomitant deletions of these genes may underlie predisposi-
tion to MEN1 and pituitary adenoma. Co-occurrence of muta-
tions in the AIP gene and the MEN1 gene is under investigation 
and may be studied in double-heterozygote animal models [35,36].
Genetic predisposition for other diseases
Genetic predisposition for other diseases may contribute to the 
enhancement of tumor formation in patients with MEN1 [37]. 
For example, normally the vitamin D receptor (VDR) on para-
thyroid cells inhibits the production and release of parathyroid 
hormone. In families with inactivating mutations in the gene 
encoding VDR, this is associated with end-organ resistance to 
calcitriol.
In the parathyroid glands of patients with MEN1, a decreased 
activation of the VDR exists. An additional defect in the VDR 
or calcium receptor may contribute to hyperactivity,  hyperplasia 
and adenoma [38].
Additional somatic mutations involved in the acceleration of 
tumor growth
Data from other familial NET syndromes  
– Phenocopies disclose similarities in pathways
How can we identify additional acquired mutations that are 
responsible for acceleration of tumor growth in MEN1? Clues 
for modifier genes may be found in other familial NET syn-
dromes like MEN2 and MEN4; the latter is also referred to as 
MENX. Which are their traditional pathogenetic pathways, and 
are these involved in aberrant clinical MEN1 expression? Overlap 
between MEN1 and MEN2 and additional genetic events has to be 
explored (e.g., p18/p27-knockout mice develop both MEN1- and 
 MEN2-associated tumors) [39,40].
Phenotypic overlap between MEN1- and MEN2-like syndromes 
was identified in the rat and named MENX. The syndrome is caused 
by a germline inactivating mutation in the CDKN1B gene, encoding 
p27Kip1 [41]. The protein p27Kip1 has a key role in cell cycle regula-
tion, and is involved in  differentiation, apoptosis and angiogenesis.
Subsequently, germline mutations in the CDKN1B gene were 
identified in the germline of a MEN1-like phenotype family. In 
these patients with pHPT and a growth hormone (GH)-producing 
pituitary tumor, germline mutations of the MEN1 gene could not 
be detected [41]. The patients were also negative for RET gene muta-
tions (MEN2). Mutations in the CDKN1B and related genes, but 
without MEN1 or MEN2 gene mutations, are a rare cause of this 
MEN1-like phenotype [42–44]. As a consequence of mutations in 
the p27 gene, a novel human MEN syndrome was recognized and 
named MEN4. The phenotypic features associated with MEN4 are 
still poorly defined due to the small number of patients reported.
In mice, another cyclin-dependent kinase inhibitor p18Ink4c 
encoded by the CDKN2C gene was shown to inhibit tumori-
genesis in endocrine tissues by collaboration with menin [45]. In 
transgenic MEN2 mice and humans with MEN2, inactivating 
mutations in p18 will promote tumor growth [39,40,46,47]. 
Reduced expression of CDKN1B, but not CDKN2C, has been 
observed in parathyroid adenomas from patients with MEN1, sug-
gesting that p27 may collaborate with menin in the  suppression 
of MEN1 tumorigenesis in humans [38].
The association of gastric carcinoids (GCs) and HPT in families 
is not always related to MEN1. This appears to constitute a dis-
tinct syndrome that can be encountered in genetically predisposed 
individuals, and should not be regarded as ‘atypical’ or ‘incomplete’ 
expression of MEN1. Its prevalence and etiology should be the 
subject of future studies. Screening for HPT seems to be justified 
in patients with GC of any type [48].
Clues from sporadic parathyroid adenomas, pituitary tumors & 
pancreatic NETs: the NET pathway  
– Parathyroid adenoma
A high rate of somatic MEN1 gene mutations is seen in sporadic 
parathyroid adenomas. An interaction exists between menin and 
the TGF-β/Smad signaling pathway. In vitro experimentation has 
demonstrated that the presence of menin is required for TGF-β to 
effectively inhibit parathyroid cell proliferation and parathyroid 
hormone production [49].
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In sporadic parathyroid adenomas, somatic mutation and 
germ line sequence abnormalities in CDKN1B, encoding 
p27Kip1, were detected in 4.6% [50]. MEN2A is caused by acti-
vating mutations of the RET proto-oncogene encoding a receptor 
tyrosine kinase. Both reduced menin activity and receptor tyros-
ine kinase activation can cause downregulation of p18 and p27, 
indicating a common pathway in these two MEN  syndromes 
(Figure 2).
In MEN1, inactivating mutations of the MEN1 gene affect 
the function of the VDR. Normally, vitamin D inhibits para-
thyroid cells from producing and releasing parathyroid hormone. 
In patients with MEN1, impaired action of vitamin D may con-
tribute to hyperplasia of the parathyroid glands. Cell division of 
parathyroid cells may make them more sensitive to additional 
mutations [38].
Pituitary adenoma
The pituitary tumor-transforming gene 
(PTTG; securin) was the first transforming 
gene found to be highly expressed in pituitary 
tumor cells, and seems to play an important 
role in the process of oncogenesis. Cell 
signaling abnormalities have been identified 
in pituitary tumors, but their genetic basis 
is unknown. Both the Raf/MEK/ERK 
and PI3K/AKT/mTOR pathways are 
overexpressed and/or overactivated in 
pituitary tumors [51]. These pathways share 
a common root, including initial activation 
by a tyrosine kinase receptor.
Pit-1 is a direct transcriptional target of 
VDR. Recruitment of histone deacety-
lase 1 is involved in the repressive effect 
of VDR on Pit-1 expression [52]. There is 
a critical role for the growth factor activin 
in regulating the inhibition of pituitary cell 
growth and Pit-1/PRL expression through 
the Smads and menin [53]. Alterations in the 
activin/TGF-β downstream signaling 
pathways may be critical steps toward 
tumor formation and progression [54]. 
Until now, the occurrence of additional 
TGF-β, Pit-1, PTTG or VDR mutations in 
 MEN1-associated tumors has not been not 
published. 
Pancreatic NETs
In nonfamilial pancreatic NETs (pNETs), 
the most commonly mutated genes 
specify proteins implicated in chromatin 
remodeling: 44% of the tumors had 
somatic inactivating mutations in MEN1. 
Clinically, mutations in the MEN1 gene 
were associated with better prognosis. 
Furthermore, mutations in genes in the 
mTOR pathway were found in 14% of the tumors, a finding 
that could potentially be used to stratify patients for treatment 
with mTOR inhibitors [55].
Loss of menin expression is associated with overexpression of 
the Raf/MEK/ERK and P13K/AKT/mTOR pathways in pancre-
atic tumors in a mouse model [56]. Intact menin has an essential 
role in Wnt/β-catenin signaling and inhibits mouse pancreatic 
islet tumor proliferation [57]. Menin regulates subcellular locali-
zation of β-catenin via nuclear–cytoplasmic shuttling. Loss of 
menin leads to Wnt/β-catenin signaling activation. Expression of 
p27 was found to be repressed in pancreatic islet cell tumors [58].
Pathways in multistep carcinogenesis
It appears that interaction of components of the PI3K/AKT 
pathway is involved in NET formation [59,60]. Deregulation of 
the PI3K/AKT pathway in NETs can occur through a range of 





















































Figure 2. Additional mutations in MEN1 neuroendocrine tumors. Beyond 
inactivation of the MEN1 gene, additional mutations in other genes may be responsible 
for acceleration of tumor growth, thus involving a process of multistep tumorigenesis. 
Deregulation of normal neuroendocrine development/differentiation can occur through a 
range of processes – for example, activation of the PI3K pathway leads to AKT 
phosphorylation, triggering a downstream cascade of events. Deregulation of this 
pathway can occur through several mechanisms: (1) Gain of function by oncogenic 
mutations of PIK3; (2) Loss of function of the tumor suppressor PTEN through gene 
deletion, mutation, miRNA expression, or epigenetic silencing; (3) Amplification or 
mutation of AKT isoforms; (4) Upstream activation through RTK signaling;  
(5) Downstream, loss of the tumor suppressors p18 and p27; (6) Increased RAS 
expression or activating mutations of RAF, MEK or ERK also will accelerate cell 
proliferation. Opportunities for treatment are represented in blue.  
AKT: Serine/threonine protein kinase (also known as PKB); Bcl-2: B-cell lymphoma 2; 
D2R: Dopamine-2 receptor; GSK3: Glycogen synthase kinase; JNK: c-Jun-N-terminal 
kinase; PTEN: Phosphate and tensin homolog; PTP-ase: Phosphotyrosine phosphatase; 
RTK: Receptor tyrosine kinase; SSTR: Somatostatin receptor; TZD: Thiazolidinedione.
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Gain of function occurs by oncogenic mutations of PI3K 
 signaling, while loss of function of the tumor suppressor PTEN 
occurs through gene deletion, mutation, miRNA expression or 
epigenetic silencing, upstream activation through receptor tyrosine 
kinase signaling and/or downstream loss of the tumor suppressors 
p18 and p27. 
A combination of a mutation in the MEN1 disease gene with 
other specific mutations of genes in the PI3K/AKT pathway may 
be associated with acceleration of tumor growth. In addition, 
inactivation or absence of menin promotes RAS expression, while 
activating  mutations of RAF, MEK or ERK may accelerate cell 
proliferation [61].
Ecogenetic factors
Common environmental factors may interact with genetic pre-
disposition to MEN1 and contribute to enhancement of tumor 
formation [37]. For example, in patients with MEN1, low vita-
min D or calcium levels may promote parathyroid gland hyper-
plasia and adenoma formation, whereas estrogenic or neurolep-
tic drugs may promote prolactinoma formation in the pituitary. 
Similarly, use of  histamine-H2 receptor or proton-pump block-
ers may stimulate cell proliferation and hence tumorigene-
sis  in the stomach (gastrinoma) [62]. Of course, as with many 
other types of tumors, the very general environmental factors 
smoking and exposure to radiation may also promote MEN1 
tumorigenesis. 
Clinical presentation, diagnosis & treatment
Parathyroid adenomas
Approximately 75–95% of patients with MEN1 develop para-
thyroid hyperplasia [63]. In MEN1, HPT has a milder presenta-
tion, but is associated with lower bone mineral density  compared 
with sporadic HPT [24].
In MEN1, pHPT may be asymptomatic and therefore in a 
proband is often unrecognized [64]. Subtotal parathyroidectomy 
is the best surgical therapy for pHPT in MEN1. In addition, a 
thymectomy should routinely be performed in these patients [65]. 
Patients suffering from MEN1 with pHPT should not be treated 
with less than subtotal parathyroidectomy because of the unaccept-
ably high rate of recurrent and persistent pHPT. In general, even 
subtotal parathyroidectomy results in a recurrence rate of >10%. 
Recurrence may occur in an initially considered normal gland, 
in a remnant of a partially excised abnormal gland, and due to a 
supernumerary gland [66].
Cryopreservation and autotransplantation of parathyroid glands 
should be performed only in experienced centers, and used only for 
patients with hyperplastic parathyroid tissue. Tissue samples should 
be systematically destroyed when patients do not have hypopar-
athyroidism or after 1 year of storage, to avoid  accumulation of 
ungrafted samples with all risks involved [67].
In MEN1, HPT is associated with a high recurrence rate 
and high surgical morbidity due to multiple neck explora-
tions. Cinacalcet, a calcimimetic agent, is an effective and well-
tolerated medical treatment for the management of complex 
pHPT [68].
Endocrine duodenum & pancreas
Approximately 55% of patients with MEN1 develop pNETs 
[69]. Multicentric microadenomas are present in 90% of these 
patients [70]. Hormonal syndromes often occur late and indi-
cate metastases in 50% of patients with MEN1 [71]. Therefore, 
prospective screening with biochemical markers and endoscopic 
ultrasound (EUS) is indicated. EUS evaluation reveals that the 
frequency of nonfunctioning pNETs is as high as 55% [72]. They 
predominantly occur in the pancreas. Negative prognostic factors 
include the presence of metastases, invasion of adjacent organs 
and perineural or angioinvasion.
Diagnosis
Monitoring of pancreatic peptides and use of diagnostic imaging 
allow an early pancreatic resection, in conjunction with  prevention 
of metastatic pNETs and improvement of long-term survival. 
Visualization
EUS has a prominent role in the screening of asymptomatic muta-
tion carriers with PET-hormone hypersecretion, and in the search 
for a pancreatic primary in case of a suspected lesion in the liver 
with unknown primary [73]. EUS and MRI are complementary [74]. 
pNETs can be visualized by ultrasound, MRI,  somatostatin 
receptor scintigraphy, computed tomography and 18F- dihydroxy-
phenylalanine-PET. 11C-5-hydroxytryptophane-PET seems 
to be more sensitive in imaging [75]. There is limited value of 
18F-dihydroxy-phenylalanine-PET in pancreatic insulinoma [76].
Treatment
The rationale for surgical considerations for pNETs is to curtail 
the malignant progression of the disease and to cure or aid in the 
management of the associated biochemical syndromes. 
However, a conservative approach of treatment in  nonfunctioning 
pNETs <20 mm in diameter is indicated. If a tumor is >3 cm in 
diameter and/or expanding, the tumor and the peripancreatic 
lymph nodes should be resected, together with duodenotomy to 
assess the presence of gastrinomas. Enucleation of tumors in the 
head of the pancreas, excision of duodenal gastrinomas, clear-
ance of lymph-node metastases and distal pancreatectomy may 
be performed to prevent recurrence [71]. Insulinomas may also be 
candidates for enucleation.
Most patients with functional syndromes eventually develop 
malignant growth. Early aggressive surgery (diameter and >1 cm) 
may prevent liver metastases [77,78]. Prevention of spread should 
be balanced against potential operative morbidity and mortality. 
Hepatic metastatic lesions can be successfully treated by surgical 
resection [79].
Gastrinomas & Zollinger–Ellison syndrome
In patients with MEN1 with Zollinger–Ellison syndrome (ZES), 
for localization of gastrinoma, selective arterial secretagogue 
injection test with secretin or calcium solution may be performed 
as well as somatostatin receptor scintigraphy. Optimal surgery may 
be performed if it is guided by localization with the selective arterial 
secretagogue injection test. Depending on extension, local resection 
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of duodenal gastrinomas with dissection of regional lymph nodes 
and for multiple duodenal gastrinomas pancreas-preserving total 
duodenectomy, may be performed. pNETs >1 cm in diameter are 
resected either by distal pancreatectomy or enucleations.
Complete resection of gastrinomas is based on accurate locali-
zation with the selective arterial secretagogue injection test and 
this may be useful for biochemical cure of gastrinoma. With this 
strategy, no hepatic metastases developed postoperatively [80].
Recurrence
Initial surgery of pancreaticoduodenal endocrine neoplasms may 
provide tumor control and prevent metastases, but recurrent tumors 
may be multifocal and progressive. In a large study, recurrence after 
initial surgery was observed in 16% of the patients. Cytoreductive 
surgery is recommended for patients with locoregional recur-
rences or hepatic metastases. Completion by pancreatectomy 
and duodenectomy seems arduous, but outcomes are acceptable. 
Considering the radical nature of this treatment, individual consid-
eration should be given to patients with MEN1 amenable to initial 
alternative pancreatic resections that preserve pancreatic mass and 
allow future pancreas-preserving  reoperations [81].
Vascular involvement
In 17% of patients with MEN1 with pNETs, computed tomo-
graphy provided suspicion of major vascular involvement. 
Extensive resection with vascular reconstruction was associated 
with a better overall survival. These findings suggest that surgical 
resection of pNETs with vascular abutment/invasion and nodal 
or distant metastases is indicated [82].
Recently, it has been suggested that regardless of the stage of 
disease at presentation, the first-line therapeutic option  for such 
patients is surgical resection [83]. For most MEN1 patients with 
pNETs, pancreatectomy with lymph-node sampling is indicated, 
either through open or laparoscopic techniques.
For patients with locoregional recurrences or hepatic meta-
stases, regional adjuvant therapy, such as radiofrequency ablation 
or transarterial chemoembolization, are often used  to reduce 
tumor load and symptoms and prolong survival. Unfortunately, 
chemotherapy is not usually in patients with extensive tumor 
load, although the somatostatin analog octreotide has shown 
some beneficial effects. Other systemic agents targeting specific 
signaling pathways, such as receptor tyrosine kinase inhibitors 
(sunitinib) and protein kinase inhibitors (everolimus), have also 
shown promising results [84].
Ectopic GH-releasing hormone production by a pNET was 
published recently and found in a woman with acromegaly. 
Secondary somatotroph hyperplasia in the pituitary gland was 
present [85,86].
Pituitary adenomas
In MEN1, pituitary tumors differ from common tumors: they 
may be larger, show multiplicity and occur at a young age. In a 
large group of patients with MEN1, pituitary adenomas occur in 
42% of cases and are characterized by a larger size and a more 
aggressive presentation than without MEN1. MEN1 pituitary 
adenomas were significantly more frequent in women than in 
men (50 vs 31%; p < 0.001). Among the 136 pituitary adenomas, 
there were 85 prolactinomas and 12 GH-secreting, six adreno-
corticotropic hormone (ACTH)-secreting, 13 cosecreting and 
20 nonsecreting tumors. Overall, 85% of MEN1-related pituitary 
lesions were macroadenomas (vs 42% in patients without MEN1; 
p < 0.001), including 32% of invasive cases. No correlation was 
found between the type of MEN1 germline mutation and the 
presence/absence of pituitary adenoma [87].
MEN1-associated adenoma may show a similar expression pro-
file to that seen in the sporadic mammosomatotropinoma (pro-
ducing both GH and prolactin). In one individual with MEN1, 
a morbid prolactinoma occurred at the age of 5 years. Hence, this 
is the earliest age at which to recommend tumor surveillance in 
carriers [21]. 
In patients with MEN1, Cushing’s syndrome (CS) from endo-
genous hypercortisolism can result from pituitary, adrenal or 
other endocrine tumors. In a total of 14 patients with CS, 11 had 
Cushing’s disease (CD) and three had ACTH-independent CS 
due to adrenal tumors, frequencies indistinguishable from sporadic 
CS [88]. CD, which is caused by an ACTH-secreting pituitary 
adenoma, is associated with increased morbidity and mortality.
The majority of ACTH-secreting adenomas simultaneously 
express somatostatin-receptor subtype 5 and dopamine-receptor 
subtype 2. Pasireotide is a new somatostatin analog that binds with 
high affinity to somatostatin receptor subtypes 1, 2 and 3, and it has 
especially high-affinity binding to somatostatin receptor subtype 
5. Pasireotide and the dopamine-receptor subtype 2 agonist caber-
goline appear to have synergistic effects in the treatment of CD 
[89]. Combination of pasireotide with ketokonazol, which inhibits 
steroidogenic enzymes in the adrenal cortex, resulted in biochemi-
cal control in nearly 90% of patients.
Adrenals
MEN1-associated ACTH-independent CS may be associated 
with aggressive adrenocortical disease, and an etiology for CS in 
MEN1 may be elusive in a substantial minority of patients [88].
In a cohort of 715 patients with MEN1, adrenal enlarge-
ment was seen in 20%. Adrenal tumors (>10 mm in diameter) 
were detected in 58% of these patients. Tumors were bilateral 
and >40 mm in size in 12 and 19% of cases, respectively [89]. 
Hormonal hypersecretion was restricted to patients with tumors 
and occurred in 15.3% of them. Compared with incidentalomas, 
MEN1-related tumors exhibited more cases of primary hyperal-
dosteronism, fewer pheochromocytomas and more adrenocortical 
carcinomas (13.8 vs 1.3%) [90]. MEN1 is a high-risk condition for 
the occurrence of adrenocortical carcinomas. They should be con-
sidered regardless of the size of the tumor, they may be  bilateral 
[91] and genotype–phenotype correlation has been  suggested [92].
Carcinoid tumors
Since currently, in MEN1, parathyroid and pituitary disease 
can be diagnosed and treated effectively, foregut carcinoids 
deserve more attention, because they are becoming important 
determinants of survival.
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Gastric carcinoids or enterochromaffin-like-cell tumors
The terms ‘GC’ or ‘gastric NET’ may also relate to tumors in 
the stomach, which originate from cells secreting gastrin or sero-
tonin. Therefore, MEN1-related gastric tumors should prefer-
ably be termed enterochromaffin-like (ECL) cell tumors. Gastrin 
stimulates ECL cells in histamine production and cell division. 
Free serum gastrin levels are strongly correlated with the α-hCG-
immunoreactivity (IR), which is a marker for ECL cells. Thus, all 
patients with MEN1/ZES have some degree of ECL cell changes; 
in 53%, these changes are advanced (at least mild hyperplasia), 
and 23% have ECL cell tumors. 
Since patients with MEN1/ZES are at risk for developing 
ECL cell tumors, they require regular gastroscopy with multiple 
biopsies of all parts of the stomach and systematic biopsies of all 
mucosal lesions to detect these carcinoids [93].
Clinical and laboratory data as well as biopsy results can be 
used to identify a subgroup of patients with MEN1/ZES with 
a significantly increased risk for developing GCs, allowing the 
development of better surveillance strategies.
The α-hCG-IR correlated significantly with the most advanced 
ECL cell change. A total of 63% of routine biopsies showed dif-
fuse hyperplasia, 17% linear hyperplasia and 5.5% micronodular 
hyperplasia [93]. Treatment involves endoscopic polypectomy, sur-
gical excision, associated or not with surgical antrectomy, or total 
gastrectomy. Moreover, the recent introduction of somatostatin 
analog represents a therapeutic option.
Thymus carcinoid
MEN1-related thymic carcinoid is often insidious with a poor 
prognosis. In a French MEN1 group, thymic tumors were exclu-
sively found in males [30], whereas in Japan, 37% of MEN1 
 thymus carcinoid was found in females [31,94].
We suggest chest MRI for patients with MEN1, and serological 
or genetic screening for sporadic patients with thymic carcinoid 
to screen for MEN1 (Box 1). 
Most thymic NETs in MEN1 are nonfunctional; however, 
ectopic ACTH can be produced by these tumors in the context 
of MEN1 [95]. In addition, thymus carcinoid may also produce 
ectopic GH-releasing hormone [96].
Bronchus carcinoid
Carcinoid tumors of bronchial origin are rare in MEN1. The prev-
alence of histologically confirmed cases is approximately 5–8%, 
although in more recent studies it is estimated that it could be 
much higher and a possible relationship with the presence of 
hypergastrinemia is suggested [30,97].
Other tumors
Prostate carcinoma
Among male mice with a heterozygous knockout of the MEN1 
gene, an increased prevalence of prostate cancer has been detected 
[81]. Expression of the p27-encoding CDKN1B gene, a transcrip-
tional target of menin, which is known to be inactivated in prostate 
tumorigenesis, was downregulated in the prostate cancers of these 
mice. In addition, expression of the androgen receptor (AR) gene, 
another putative target of menin, was altered in these tumors as 
compared with AR gene expression in prostate glands of wild-type 
control mice [98]. 
Breast cancer
Among female mice with a heterozygous knockout of the 
MEN1 gene, 8% had breast cancer [98]. Perhaps p27 may be 
 downregulated in some of these tumors. Intact menin binds to 
the estrogen receptor and may enhance its activity in breast cancer 
cells. In patients with MEN1, however, this promoting factor 
is not available and this may attenuate cell division and predict 
tamoxifen resistance [99].
The simultaneous occurrence of mutations in two different 
tumor suppressor genes in the same individual is a very rare event. 
However, a germline mutation in the BRCA1 gene in a woman 
with familial MEN1 was observed, and resulted in a combination 
of MEN1 and an inherited breast–ovarian cancer syndrome [100]. 
The severity of MEN1-related biochemical and clinical findings 
did not significantly differ from that of other affected family mem-
bers lacking the BRCA1 mutation, except for the  development of 
an extremely large visceral lipoma.
Lipoma & hybernoma
Menin is an important factor in PPAR-γ-mediated adipogenesis, 
and loss of PPAR-γ function may contribute to lipoma develop-
ment in patients with MEN1 [101]. A balanced translocation 
deleting the wild-type MEN1 allele primed the lipoma develop-
ment [102]. Hibernomas are benign tumors with morphological 
features resembling brown fat. They consistently display cytoge-
netic rearrangements, typically translocations, involving chromo-
some band 11q13. Hybernomas are associated with concomitant 
deletions of AIP and MEN1, located 3 Mb apart. MEN1 and 
AIP displayed a low expression in hibernomas [103]. Compared 
with lipoma, in hibernoma there are low transcript levels of 
MEN1 and AIP.
Metabolic effects of aberrant expression of the MEN1 
gene
In MEN1 disease gene carriers, all VDRs and PPAR-γs are 
expressed, but are probably less activated owing to  impaired 
menin function.
PPAR-γ-2 is a transcription factor that has a key role in adipo-
cyte differentiation. Polymorphisms in this gene may contribute 
to the variability in BMI and insulin sensitivity in the general 
population. PPAR-γ is the receptor for the thiazolidinediones, 
which act as PPAR-γ agonists and lower the blood glucose levels 
in patients with Type 2 diabetes mellitus by increasing insulin 
sensitivity.
Individuals with dominant-negative PPAR-γ gene mutations 
manifest a syndrome that combines lipodystrophy with features 
of the metabolic syndrome, including insulin resistance, Type 2 
diabetes, hepatic steatosis, dyslipidemia, hypertension and 
polycystic ovary syndrome in women. In patients with MEN1, 
decreased activation of PPAR-γ may result in insulin resistance 
and weight gain [104].
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VDRs are found in a large number of tissues beyond the classic 
target tissues gut, bone and kidney. These tissues include endocrine 
glands such as the pituitary and parathyroid glands, and pancreatic 
islets, among others.
Lourenço et al. discussed the increased bone loss pattern found 
in patients with MEN1 compared with that of patients with 
sporadic primary HPT [24]. Besides increased bone loss, resist-
ance to vitamin D may be associated with insulin resistance and 
β-cell dysfunction, leading to increased risk for Type 2 diabetes 
in patients with MEN1 [105,106].
Screening
In MEN1-suspected patients, mutational analysis helps to con-
firm the clinical diagnosis. It may identify asymptomatic family 
members who have close relatives with a MEN1 gene mutation. 
Otherwise, they require periodical screening from an early age. 
Genetic screening may also identify the 50% of family members 
who do not have the MEN1 mutation and can therefore have 
the burden of screening and anxiety regarding potential disease 
removed. Moreover, MEN1 mutational analysis helps to resolve 
diagnostic challenges due to phenocopies, which occur in 5–10% 
of families with MEN1.
Active MEN1 family investigation is strongly recommended. 
The successful identification of patients with MEN1 among 
close relatives will result in an increase in the number of patients 
requiring clinical screening. Surveillance and treatment have 
 implications in the planning of future service provision. 
An early genetic diagnosis allows early periodical screening. It 
facilitates clinical management and provides benefits to patients 
and families concerning morbidity, quality of life and life expec-
tancy [107,108]. In children, MEN1 gene mutational analysis should 
be advised before periodical screening is started, in other words 
at the age of 10 years. However, parents should be free to decide 
to carry out DNA analysis at an earlier age. Information about 
screening may be provided from the age of 5 years (Box 2).
Owing to the variety in expression, it is not easy to establish 
general guidelines for periodical screening. In some families, the 
age at which symptoms and signs occur is quite young (Box 1) [21,109].
The development of a dedicated multidisciplinary MEN clinic 
will improve the diagnosis and treatment of MEN1-associated 
endocrinopathies [110]. A case manager who has an overview 
and primary responsibilities is needed. This clinician knows the 
 medical history of the patient and has an affinity to this complex 
disease.
Box 1. Periodic clinical screening.
Eligible for periodic clinical monitoring are:
• MEN1 patients
• MEN1 gene germline mutation carriers
• MEN1-suspected patients without a confirmed mutation: DNA analysis has to be recommended and performed in advance
Periodic screening includes†:
• From the age of 10 years: biannual clinical examination:
– Medical history: are suspected symptoms present?
– Laboratory investigation:
– Including measurement in blood of: total/ionized calcium, chloride, phosphate, parathyroid hormone, glucose, insulin, C-peptide, 
glucagon, gastrin, pancreatic polypeptide, prolactin, IGF-I, platelet serotonin and chromogranin A
• From the age of 15: once every 2 years†:
– MRI of the upper abdomen
– MRI of the pituitary with gadolinium contrast
– MRI of the mediastinum in males and females (annual screening preferred)
†In families with early manifestation of the disease or if suspicion arises because of clinical symptoms, early screening is recommended; if clinical suspicion regarding 
insulinomas is present, a fasting test should not be postponed; use of proton-pump inhibitors or H2-receptor blockers may increase gastrin and chromogranin A 
levels; oral contraceptives may increase prolactin levels. 
MEN1: Multiple endocrine neoplasia type 1.
Box 2. Suggested criteria for MEN1 gene mutation analysis.
MEN1 gene mutation analysis should be offered to:
• Patients with MEN1
• Patients with three out of five major MEN1-associated lesions: parathyroid adenomas, pancreatic islet cell tumors, pituitary adenomas, 
adrenal adenomas and NETs
• First-degree family members (parents, brothers, sisters and children) of patients with MEN1 or asymptomatic MEN1 gene germline 
mutation carriers; in children before periodical screening is started – in other words, at the age of 10 years
• MEN1-suspected sporadic patients: with two out of the five major lesions, two MEN1-associated tumors within one organ and/or a 
MEN1-associated tumor at a young age (<35 years)
MEN1: Multiple endocrine neoplasia type 1; NET: Neuroendocrine tumor.
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Conclusion
Observation of the expression of MEN1, and collaboration among 
disciplines including genetics and molecular endocrinology, 
opened up new directions in the management of MEN1 syndrome 
and promoted the development of novel target-directed therapy. 
Since 1980, life expectancy and quality of life have improved 
considerably.
MEN1 is a disease with variable expression that may occur at a 
young age; the symptoms may be general and the lesions small. At 
present, patients become aged and may show metabolic disorders 
like osteoporosis, obesity and diabetes mellitus as a consequence 
of menin inactivation.
Nucleotide sequence analysis enables the identification of 
MEN1 disease gene carriers. Periodic clinical monitoring enables 
presymptomatic detection of expression. DNA diagnosis should 
be established before the age of 10 years.
Malignant thymic tumors and duodenopancreatic tumors, 
including nonsecreting pancreatic tumors, ECL tumors of the 
stomach and rare but aggressive adrenal carcinomas, increase 
the risk of early death. In MEN1 disease gene carriers in MEN1 
families, most deaths were related to progressive disease and 
probably resulted from additional mutations [111].
It is possible that consecutive and specific pathogenetic path-
ways are involved in MEN1 tumor formation. We presume that, 
through the inherited germline mutation resulting in organ-
specific cell division, the patient is vulnerable to additional, 
somatic mutations in these organs. These mutations may occur 
spontaneously or may be triggered by lifestyle and/or environ-
ment. Predisposition and expression of other genetic diseases 
may also be involved.
A complex genotype–phenotype relationship may be present. 
Unfortunately, currently in the majority of patients, it is not 
 possible to predict the course of the disease.
Germline mutations that result in complete inactivation of the 
gene product, apparently cause more severe disease. Consequently, 
extensive periodic clinical examination should be performed in all 
MEN1 disease gene carriers to detect progressive disease. 
Expert commentary
Family investigation and genetic linkage studies have led to 
identification of the gene that has germline mutations in MEN1. 
Periodic clinical screening of patients has improved the life expec-
tancy and quality of life. The mechanism of disease on a cel-
lular level was investigated and cell type-dependent and  specific 
 signaling pathways have been established.
The risk for development of malignant tumors may justify 
early preventive surgical treatment. Genetic testing involves loss 
of privacy and autonomy, stigmatization and discrimination, 
and psychological care in attendance of families is indispensible. 
Furthermore, social attitude to rare hereditary diseases has to be 
adapted and preventive care needs to be facilitated; a safety net 
must involve clinical staff, laboratory facilities, patient and fam-
ily registration, and practical nurses coordinating clinical care. 
Currently, these facilities are not incorporated into clinical care. In 
the future, these should be financed by health insurance companies 
and/or the government, and standardized guidelines will need to 
be maintained and adapted continuously.
Five-year view
Until now, collaboration among basic scientists and a network 
of physicians resulted in improvement in the management of 
patients with MEN1. In the near future, however, subspecializa-
tion in medicine and lack of knowledge on molecular endocri-
nology in medical specialists may slow down this progress. Who 
has general responsibility for patients and an overview about 
opportunities in treatment? 
Early DNA analysis allows identification of predisposition to 
MEN1; considering DNA analysis as a clinical test would relieve 
noncarriers from the burden of periodical investigations. Moreover, 
the clinical tests are expensive, and discussions about reimburse-
ment of these tests by insurance companies without identification 
by DNA analysis are ongoing. Thus, in children, DNA analysis 
is recommended before periodical screening is started – in other 
words, at the age of 10 years.
Functional analysis of menin protein mutants is required to 
study the true effect of specific MEN1 gene mutations.In embry-
onic stem cells, menin-dependent development of tissue specificity 
will be studied. In the near future, tumor gene-expression profiles 
and high-throughput sequencing may permit more insight into 
additional genetic and epigenetic events and mechanisms in multi-
step carcinogenesis that cause progression of tumor development. 
Target-directed treatment for tumors with additional mutations 
and aggressive behavior will be available. 
Preimplantation genetic diagnosis enables selection of embryos 
without MEN1 disease gene mutations for implantation. 
Preimplantation genetic diagnosis is an alternative that should 
be offered to prospective parents, and represents a method to 
decrease and potentially eliminate the disease transmission 
of MEN1 [112]. Increasing the awareness of clinicians to the 
 availability of these methods is most important.
miRNAs inhibit protein translation from the target mRNA. 
The miRNA-expression profiles may become useful biomarkers 
for endocrine tumor development.
Experimental studies have shown that dysregulation of miRNAs 
is responsible for endocrine carcinogenesis, including pancreatic, 
pituitary and parathyroid tumors. Depending on the expression 
profile, miRNAs may become potential targets for therapeutic 
strategies [113].
siRNAs are a class of double-stranded RNA molecules, 20–25 
nucleotides in length, which may have a silencing effect on RNAs 
responsible for cell division [114]. This may be a basis for the develop -
ment of RNA-based therapies in MEN1 gene  mutation carriers. 
The significance of MEN1 Patient Alliances or Interest Groups 
is as follows:
•	 They may support individual problems, such as loss of 
privacy, stigmatization, discrimination, emotional distress and 
managing psychological problems;
•	 They are promoting the maintenance of continuous clinical care, 
and may discuss the costs of preventive periodical investigation;
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•	 They stand up for common interests like social, ethical, 
 insurance and employment issues;
•	 At this moment and in the future, Family Interest Groups are of 
essential value, and they will play a prominent role and promote 
guidance and care;
•	 They are becoming a necessary supplement to modern, 
 specialized medicine.
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Key issues
• A clear definition for patients with clinically suspected multiple endocrine neoplasia type 1 (MEN1) promotes identification: a case with 
at least two out of the three main MEN1-related endocrine tumors (parathyroid hyperplasia/adenomas, enteropancreatic endocrine 
tumors and pituitary tumors).
• Malignancy: most harmful MEN1 tumors are pancreatic–duodenal gastrinomas, thymus carcinoid, enterochromaffin cell-like tumors of 
the stomach and adrenal carcinomas.
• MEN1 is caused by mutations in the MEN1 tumor supressor gene; DNA analysis permits identification presymptomatically.
• Patients with MEN1, their family members, family members of MEN1 gene mutation carriers and patients who are clinically suspected 
to be carriers of a MEN1 gene mutation are eligible for MEN1 gene mutation analysis.
• MEN1-associated tumors can be detected and treated at an early stage through periodic clinical monitoring of MEN1 gene mutation 
carriers according to guidelines.
• Patients interest groups or alliances may help in medical, psychological, social and ethical problems.
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